Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:51:15 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Z:CVM - CEL-SCI CORP - http://www.cel-sci.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CVM - Z0.11.20·1.800.11.27-0.109-7.9471.25758781.41  1.41  1.253.23  1.0416:17:30May 1615 min RT 2¢

Recent Trades - Last 10 of 878
Time ETExPriceChangeVolume
16:17:30Z1.37-0.0320
16:16:14Z1.37-0.031,615
16:13:20Z1.31-0.09200
16:12:08Z1.31-0.09100
16:10:12Z1.2908-0.10925
16:07:06Z1.3092-0.0908200
16:06:26Z1.3083-0.0917300
16:03:31Z1.2707-0.12932
16:00:05Z1.27-0.13400
16:00:05Z1.28-0.12400

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-16 09:00U:CVMNews ReleaseCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
2024-05-08 09:00U:CVMNews ReleaseCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
2024-04-23 09:00U:CVMNews ReleaseCEL-SCI Appoints Mario Gobbo to Its Board of Directors
2024-03-19 09:00U:CVMNews ReleaseCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
2024-03-06 08:45U:CVMNews ReleaseCEL-SCI Corporation Issues Letter to Shareholders
2024-02-15 08:00U:CVMNews ReleaseCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
2024-02-13 12:00U:CVMNews ReleaseCEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
2024-02-09 08:30U:CVMNews ReleaseCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
2024-02-06 09:00U:CVMNews ReleaseCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
2024-01-31 09:00U:CVMNews ReleaseEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine ‚ ®
2023-12-04 08:30U:CVMNews ReleaseUK ¢ € ™S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI ¢ € ™s Multikine as Potential New Standard of Care for Head & Neck Cancer
2023-11-20 16:15U:CVMNews ReleaseCEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
2023-11-16 08:30U:CVMNews ReleaseCEL-SCI Announces Pricing of $5 Million Offering of Common Stock
2023-10-30 09:20U:CVMNews ReleaseCEL-SCI Issues Letter to Shareholders
2023-10-24 08:00U:CVMNews ReleaseCEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
2023-10-23 09:15U:CVMNews Release5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI ¢ € ™s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
2023-10-19 08:00U:CVMNews ReleaseCEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
2023-10-05 08:45U:CVMNews ReleaseCEL-SCI Files Request With the UK ¢ € ™s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
2023-09-26 09:00U:CVMNews ReleaseCEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
2023-08-11 08:00U:CVMNews ReleaseCEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results